紫素为主的化疗联合放疗增加乳腺癌患者放射性肺炎危险性的分析

Assessment of the Risk for Developing Radiation Pneumonitis Caused by Paclitaxel-based Chemotherapy plus Radiotherapy in Breast Cancer Patients

目的:评价紫素为主的化疗联合放疗增加乳腺癌患者放射性肺炎的危险性。方法:回顾性分析276例行联合放化疗的乳腺癌患者放射性肺炎的发病率,其中215例患者为术后三野放疗,61例为保乳术后切线放疗,依照辅助化疗方案的不同分为3个组,即PA组(紫素与阿霉素),CAF组(环磷酰胺,阿霉素,氟脲嘧啶),CMF组(环磷酰胺,氨甲喋呤,氟脲嘧啶),比较各组间放射性肺炎的发病率。结果:PA组放射性肺炎的发病率高于其它两组,而其他两组间比较差异无显著性。结论:紫素为主的化疗增加了乳腺癌患者放射性肺炎的发病危险。

Objective： To assess the risk of radiation pneumonitis caused by paclitaxel-based chemotherapy plus radiotherapy in breast cancer patients. Methods： The incidence of radiation pneumonitis in 276 breast cancer patients receiving chemotherapy plus radiotherapy was retrospectively analyzed. Of the 276 patients, 215 were treated postoperatively with three fields of radiotherapy and 61 were treated with whole-breast tangent radiotherapy following breast-conserving surgery. Based on various chemotherapeutic regimens, the patients were divided into 3 groups： the PA （Paclitaxel and Adriamycin） group, CAF （Cyelophosphamide, Adriamycin, Fluorouracil） group and CMF （Cyclophosphamide, MTX, Fluorouracil） group. The rate of radiation pneumonitis in these groups was compared. Results： The risks for developing radiation pneumonitis in the PA group are higher than in the other two groups. There is no significant difference between the other two groups. Conclusion： Paclitaxel-based chemotherapy increases the risk of radiation pneumonitis in breast cancer patients.